MIM
IMRX icon

MetLife Investment Management’s Immuneering IMRX Stock Holding History

MetLife Investment Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,257
Closed -$82.7K – 2800
2023
Q4 		$82.7K Hold
11,257
– – ﹤0.01% 2682
2023
Q3 		$86.5K Hold
11,257
– – ﹤0.01% 2650
2023
Q2 		$114K Buy
+11,257
New +$108K ﹤0.01% 2596
2021
Q4 		– Sell
-3,719
Closed -$98.7K – 2524
2021
Q3 		$98.7K Buy
+3,719
New +$99.9K ﹤0.01% 2443

Other funds holding IMRX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MetLife Investment Management's IMRX Position: Q1 2024 in Review

MetLife Investment Management sold out of Immuneering (IMRX) in Q1 2024, closing a stake of 11,257 shares — an estimated $82.7K sold.

MetLife Investment Management first reported a position in IMRX in Q3 2021 and held it in 4 quarters. The position peaked at $114K in Q2 2023. 51 funds tracked by Wall St. Rank hold IMRX as of Q1 2024.

  • MetLife Investment Management reported no remaining Immuneering position as of Q1 2024 after selling out during the quarter.
  • MetLife Investment Management sold 11,257 Immuneering shares in Q1 2024, an estimated $82.7K.
  • MetLife Investment Management first reported a position in Immuneering in Q3 2021 and held it in 4 quarters.
  • MetLife Investment Management's Immuneering position peaked at $114K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Immuneering as of Q1 2024.

Based on MetLife Investment Management's 13F filing for Q1 2024, filed 14 May 2024.